drugset / Trial / NCT04645953

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

NCT04645953

Phase 2 Completed 150 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.

Timeline

Start
2021-02-05
Primary completion
2022-07-26
Completion
2022-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 1 mg Inhaled
Subject Granisetron Other / unclassified 3 mg Inhaled